Synplogen Co., Ltd.

Japan

Back to Profile

1-21 of 21 for Synplogen Co., Ltd. Sort by
Query
Aggregations
IP Type
        Patent 14
        Trademark 7
Jurisdiction
        World 13
        United States 6
        Canada 2
Date
2024 December 1
2024 November 1
2024 6
2023 4
2022 4
See more
IPC Class
C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material 6
C12N 15/34 - Proteins from DNA viruses 5
C12N 15/35 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus 5
C12N 15/86 - Viral vectors 5
C12N 15/864 - Parvoviral vectors 5
See more
Status
Pending 3
Registered / In Force 18

1.

PRODUCTION OF SUBSTANCE BY STRAIN

      
Application Number JP2024020950
Publication Number 2024/253207
Status In Force
Filing Date 2024-06-07
Publication Date 2024-12-12
Owner SYNPLOGEN CO., LTD. (Japan)
Inventor
  • Miyamoto, Naoki
  • Tsuge, Kenji

Abstract

The present disclosure provides a method for producing a microbial strain exhibiting a desired property, such as high-throughput productivity and a property to reduce by-products, by activating a gene group. More specifically, in one aspect, the present disclosure provides a method for producing a strain having a desired property, the method comprising: (1) a step for providing a plurality of constructs including gene clusters each containing a plurality of genes, wherein promoters are arranged in a monocistronic configuration; (2) a step for preparing a combinatorial library of promoters in the constructs to introduce the promoters into a target host cell; and (3) a step for selecting a strain having a desired property in the host cell.

IPC Classes  ?

  • C12N 1/21 - Bacteria; Culture media therefor modified by introduction of foreign genetic material
  • C12N 1/15 - Fungi ; Culture media therefor modified by introduction of foreign genetic material
  • C12N 1/19 - Yeasts; Culture media therefor modified by introduction of foreign genetic material
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 15/52 - Genes encoding for enzymes or proenzymes
  • C12P 1/00 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymes; General processes for the preparation of compounds or compositions by using microorganisms or enzymes
  • C12Q 1/06 - Quantitative determination
  • C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors

2.

PRODUCTION OF VIRUS VECTOR PLASMID IN BACILLUS SUBTILIS

      
Application Number 18251737
Status Pending
Filing Date 2021-11-02
First Publication Date 2024-11-28
Owner Synplogen Co., Ltd. (Japan)
Inventor
  • Saito, Shunsuke
  • Tsuge, Kenji

Abstract

The present disclosure pertains to production of a virus vector plasmid in Bacillus subtilis. According to one aspect, the present disclosure provides a method for producing a virus vector plasmid having a sequence to be replicated in Bacillus subtilis. The method includes a step for forming a plasmid in a host cell by introducing, into the host cell, a nucleic acid that has a sequence to be replicated in Bacillus subtilis and that includes a nucleic acid sequence for producing a virus vector. In one embodiment, Bacillus subtilis could have the ability to form a plasmid from a nucleic acid acquired from outside, and therefore, in this method, the nucleic acid introduced does not have be a plasmid.

IPC Classes  ?

3.

ITR-REP GENE COMPLEX

      
Application Number JP2024004838
Publication Number 2024/172027
Status In Force
Filing Date 2024-02-13
Publication Date 2024-08-22
Owner SYNPLOGEN CO., LTD. (Japan)
Inventor
  • Nishimura, Yuya
  • Saito, Shunsuke

Abstract

The present disclosure provides a Rep and ITR-containing plasmid DNA or DNA/cationic substance complex having a high adeno-associated virus (AAV) vector productivity. More specifically, in one exemplary aspect, the present disclosure provides a nucleic acid, etc., the nucleic acid containing a Rep gene derived from an AAV of a first serotype and an inverted terminal repeat (ITR) sequence derived from an AAV of a second serotype different from the first serotype and having a ΔG value ranging from -65 to -95 kcal/mol.

IPC Classes  ?

  • C12N 15/864 - Parvoviral vectors
  • C12N 15/34 - Proteins from DNA viruses
  • C12N 15/35 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
  • C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

4.

HELPER GENE

      
Application Number JP2024002944
Publication Number 2024/162359
Status In Force
Filing Date 2024-01-30
Publication Date 2024-08-08
Owner SYNPLOGEN CO., LTD. (Japan)
Inventor
  • Nishimura, Yuya
  • Saito, Shunsuke

Abstract

The present disclosure provides a virus-derived gene that can be used for producing a new virus-derived construct. In more detail, the virus-derived gene according to the present disclosure includes a combination between an adenovirus-derived gene and a herpesvirus-derived gene. In one embodiment, the herpesvirus-derived gene is a gene involved in gene replication. In one embodiment, the herpesvirus-derived gene encodes a protein selected from helicase, primase, ssDNA binding proteins (DBPs), DNA polymerase, and DNA replication proteins. In one embodiment, the herpesvirus-derived gene encodes a protein selected from ssDNA binding proteins (DBPs) and DNA polymerase. In one embodiment, the herpesvirus-derived gene includes a gene selected from UL44, UL54, and UL57.

IPC Classes  ?

  • C12N 15/34 - Proteins from DNA viruses
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
  • C12N 15/38 - Herpetoviridae, e.g. herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, pseudorabies virus
  • C12N 15/54 - Transferases (2)
  • C12N 15/55 - Hydrolases (3)
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N 15/864 - Parvoviral vectors
  • C12N 15/90 - Stable introduction of foreign DNA into chromosome

5.

ARTIFICIALLY SYNTHESIZED NUCLEIC ACID FOR INCREASING PROTEIN EXPRESSION

      
Application Number JP2024002945
Publication Number 2024/162360
Status In Force
Filing Date 2024-01-30
Publication Date 2024-08-08
Owner SYNPLOGEN CO., LTD. (Japan)
Inventor
  • Hosoda, Nao
  • Hayashi, Kentaro
  • Tsuge, Kenji

Abstract

The present disclosure provides a nucleic acid construct that can control protein expression. Specifically, the present disclosure provides a nucleic acid construct including a 5' untranslated region (UTR) and a 3' UTR that are at least partially complementary to one another, wherein when at least one UTR includes a non-complementary section and a complementary section with regard to the other UTR and the length of each non-complementary section is one base, the complementarity percentage of the 3' UTR to the 5' UTR is greater than 75%.

IPC Classes  ?

  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof

6.

HELPER GENE CONTROL

      
Application Number JP2023046813
Publication Number 2024/143429
Status In Force
Filing Date 2023-12-26
Publication Date 2024-07-04
Owner SYNPLOGEN CO., LTD. (Japan)
Inventor
  • Nishimura, Yuya
  • Saito, Shunsuke

Abstract

The present disclosure provides expression control for the Rep gene by expression control of a helper gene. One aspect of the present disclosure provides a method for controlling the expression of the Rep gene that includes a step for controlling the expression of a helper gene. In one embodiment, the helper gene includes a gene selected from among adenovirus E1B, E2, E4, and VA. In one embodiment, the helper gene includes the adenovirus E1B gene. In one embodiment, the helper gene includes two or more helper genes related to production of a structure derived from an adeno-associated virus (AAV), and, as necessary, the helper gene can be selected from among E1A, E1B, E2, E4, and VA. In one embodiment, the helper gene includes a helper gene selected from among E1A and E1B and a helper gene selected from among E2, E4, and VA.

IPC Classes  ?

  • C12N 15/864 - Parvoviral vectors
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
  • C12N 15/34 - Proteins from DNA viruses
  • C12N 15/35 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus

7.

PLASMID FOR VIRUS-DERIVED STRUCTURE

      
Application Number JP2023017131
Publication Number 2023/214579
Status In Force
Filing Date 2023-05-02
Publication Date 2023-11-09
Owner SYNPLOGEN CO., LTD. (Japan)
Inventor
  • Saito, Shunsuke
  • Tsuge, Kenji
  • Nishimura, Yuya

Abstract

The present disclosure provides the production of a plasmid for a virus-derived structure. In one aspect, the present disclosure provides a plasmid that codes for at least some elements of a virus-derived structure. In one embodiment, the present disclosure provides a plasmid that is operably linked to and includes at least part of a nucleic acid sequence which is necessary to configure a virus-derived composition. In the one embodiment, the nucleic acid sequence which is necessary to configure the virus-derived composition includes (A) a nucleic acid sequence that includes a terminal repeating sequence, (B) a nucleic acid sequence that codes for a packaging factor, (C) a nucleic acid sequence that codes for a structural protein, and (D) a nucleic acid sequence that codes for a functional auxiliary factor.

IPC Classes  ?

  • C12N 15/86 - Viral vectors
  • C12N 1/15 - Fungi ; Culture media therefor modified by introduction of foreign genetic material
  • C12N 1/19 - Yeasts; Culture media therefor modified by introduction of foreign genetic material
  • C12N 1/21 - Bacteria; Culture media therefor modified by introduction of foreign genetic material
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 15/35 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
  • C12N 15/38 - Herpetoviridae, e.g. herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, pseudorabies virus
  • C12N 15/48 - Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus
  • C12N 15/864 - Parvoviral vectors
  • C12N 15/867 - Retroviral vectors

8.

VIRUS-DERIVED CONSTRUCT PLASMID LIBRARY AND CONSTRUCTION OF SAME

      
Application Number JP2023017130
Publication Number 2023/214578
Status In Force
Filing Date 2023-05-02
Publication Date 2023-11-09
Owner SYNPLOGEN CO., LTD. (Japan)
Inventor
  • Saito, Shunsuke
  • Tsuge, Kenji
  • Nishimura, Yuya

Abstract

In one aspect, the present disclosure provides a method for producing various virus-derived construct plasmids from starting plasmids (for example, the virus-derived construct plasmids of the present disclosure). In one embodiment, the method for producing virus-derived construct plasmids according to the present disclosure includes: a step for preparing a set of starting plasmids containing at least a portion of a nucleic acid sequence necessary for forming a virus-derived construct, the set of starting plasmids including a set of corresponding alternative unit nucleic acids, and the set of corresponding alternative unit nucleic acids including at least one set of corresponding alternative unit nucleic acids that contain a different nucleic acid sequence; a step for treating the set of starting plasmids with a restriction enzyme and preparing a mixed solution containing cleaved alternative unit nucleic acid fragments; a step for ligating the cleaved alternative unit nucleic acid fragments to form an integrated nucleic acid; and a step for causing the integrated nucleic acid to contact a transformed organism and thereby forming virus-derived construct plasmids.

IPC Classes  ?

  • C12N 15/86 - Viral vectors
  • A61K 35/76 - Viruses; Subviral particles; Bacteriophages
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61P 43/00 - Drugs for specific purposes, not provided for in groups
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
  • C12N 15/12 - Genes encoding animal proteins
  • C12N 15/37 - Papovaviridae, e.g. papillomaviruses, polyomavirus, SV40
  • C12N 15/48 - Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus
  • C12N 15/52 - Genes encoding for enzymes or proenzymes
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
  • C12N 15/861 - Adenoviral vectors
  • C12N 15/863 - Poxviral vectors, e.g. vaccinia virus
  • C12N 15/864 - Parvoviral vectors
  • C12N 15/867 - Retroviral vectors
  • C12N 15/869 - Herpesviral vectors
  • C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

9.

Combi-OGAB

      
Application Number 1735969
Status Registered
Filing Date 2023-03-31
Registration Date 2023-03-31
Owner Synplogen Co., Ltd. (Japan)
NICE Classes  ? 42 - Scientific, technological and industrial services, research and design

Goods & Services

Research and development relating to DNA synthesis technology; technical advisory services relating to DNA synthesis technology; research and development relating to production and analysis of virus vector; technological advisory services relating to production and analysis of virus vector; research and development relating to production and analysis of mRNA; technological advisory services relating to production and analysis of mRNA; research and development relating to gene therapy; technical advisory services relating to gene therapy research; technological advisory services relating to productization of gene therapy products; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, and technical advisory services relating thereto in the fields of protein, antibody, vaccine, virus, virus vector, mRNA, microorganisms, and cells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; technical advisory services relating to genome synthesis technology; research and development, and technical advisory services relating thereto in the fields of protein, vaccine, virus, virus vector, mRNA, antibody, microorganisms, and cells, all with genome synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems, all with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testing, inspection, and research of pharmaceuticals, gene therapy products, regenerative medical products, cosmetics or foodstuffs, all with genome synthesis technology; development of pharmaceuticals, gene therapy products, regenerative medical products, cosmetics or foodstuffs, all with genome synthesis technology; technical advisory services relating to development of pharmaceuticals, gene therapy products, regenerative medical products, cosmetics or foodstuffs, all with genome synthesis technology; quality testing, inspection, and research relating to medical treatment or medical technology with genome synthesis technology; testing and research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; research and development relating to production and analysis of virus vector for others; research and development relating to gene therapy products for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; quality testing, inspection, and research in the fields of agriculture, livestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; research and development in the field of gene expression systems; research and development in the fields of microorganisms and cells; research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; bacteriological research; biological research.

10.

COMBI-OGAB

      
Serial Number 79372347
Status Registered
Filing Date 2023-03-31
Registration Date 2024-05-28
Owner Synplogen Co., Ltd. (Japan)
NICE Classes  ? 42 - Scientific, technological and industrial services, research and design

Goods & Services

Research and development relating to DNA synthesis technology; technical advisory services relating to DNA synthesis technology; research and development relating to production and analysis of virus vector; technological advisory services relating to production and analysis of virus vector; research and development relating to production and analysis of mRNA; technological advisory services relating to production and analysis of mRNA; research and development relating to gene therapy; technical advisory services relating to gene therapy research; technological advisory services relating to productization of gene therapy products; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, and technical advisory services relating thereto in the fields of protein, antibody, vaccine, virus, virus vector, mRNA, microorganisms, and cells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; technical advisory services relating to genome synthesis technology; research and development, and technical advisory services relating thereto in the fields of protein, vaccine, virus, virus vector, mRNA, antibody, microorganisms, and cells, all with genome synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems, all with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testing, inspection, and research of pharmaceuticals, gene therapy products, regenerative medical products, cosmetics or foodstuffs, all with genome synthesis technology; development of pharmaceuticals, gene therapy products, regenerative medical products, cosmetics or foodstuffs, all with genome synthesis technology; technical advisory services relating to development of pharmaceuticals, gene therapy products, regenerative medical products, cosmetics or foodstuffs, all with genome synthesis technology; quality testing, inspection, and research relating to medical treatment or medical technology with genome synthesis technology; testing and research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; research and development relating to production and analysis of virus vector for others; research and development relating to gene therapy products for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; quality testing, inspection, and research in the fields of agriculture, livestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; research and development in the field of gene expression systems; research and development in the fields of microorganisms and cells; research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; bacteriological research; biological research

11.

PRODUCTION OF VIRUS VECTOR PLASMID IN BACILLUS SUBTILIS

      
Document Number 03200833
Status Pending
Filing Date 2021-11-02
Open to Public Date 2022-05-12
Owner SYNPLOGEN CO., LTD. (Japan)
Inventor
  • Saito, Shunsuke
  • Tsuge, Kenji

Abstract

The present disclosure pertains to production of a virus vector plasmid in Bacillus subtilis. According to one aspect, the present disclosure provides a method for producing a virus vector plasmid having a sequence to be replicated in Bacillus subtilis. The method includes a step for forming a plasmid in a host cell by introducing, into the host cell, a nucleic acid that has a sequence to be replicated in Bacillus subtilis and that includes a nucleic acid sequence for producing a virus vector. In one embodiment, Bacillus subtilis could have the ability to form a plasmid from a nucleic acid acquired from outside, and therefore, in this method, the nucleic acid introduced dose not have be a plasmid.

IPC Classes  ?

  • C12N 15/70 - Vectors or expression systems specially adapted for E. coli
  • C12N 15/75 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
  • C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts

12.

PRODUCTION OF VIRUS VECTOR PLASMID IN BACILLUS SUBTILIS

      
Application Number JP2021040410
Publication Number 2022/097646
Status In Force
Filing Date 2021-11-02
Publication Date 2022-05-12
Owner SYNPLOGEN CO., LTD. (Japan)
Inventor
  • Saito, Shunsuke
  • Tsuge, Kenji

Abstract

The present disclosure pertains to production of a virus vector plasmid in Bacillus subtilis. According to one aspect, the present disclosure provides a method for producing a virus vector plasmid having a sequence to be replicated in Bacillus subtilis. The method includes a step for forming a plasmid in a host cell by introducing, into the host cell, a nucleic acid that has a sequence to be replicated in Bacillus subtilis and that includes a nucleic acid sequence for producing a virus vector. In one embodiment, Bacillus subtilis could have the ability to form a plasmid from a nucleic acid acquired from outside, and therefore, in this method, the nucleic acid introduced dose not have be a plasmid.

IPC Classes  ?

  • C12N 15/70 - Vectors or expression systems specially adapted for E. coli
  • C12N 15/75 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
  • C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts

13.

INTEGRATIVE PLASMID

      
Document Number 03200835
Status Pending
Filing Date 2021-11-02
Open to Public Date 2022-05-12
Owner SYNPLOGEN CO., LTD. (Japan)
Inventor
  • Saito, Shunsuke
  • Tsuge, Kenji

Abstract

The present disclosure pertains to production of a virus vector plasmid. According to one aspect, the present disclosure provides a method for producing a virus vector plasmid having a sequence to be replicated in Bacillus subtilis. The method includes a step for forming a plasmid in a host cell by introducing, into the host cell, a nucleic acid that has a sequence to be replicated in Bacillus subtilis and that includes a nucleic acid sequence for producing a virus vector. In one embodiment, Bacillus subtilis could have the ability to form a plasmid from a nucleic acid acquired from outside, and therefore, in this method, the nucleic acid introduced dose not have be a plasmid.

IPC Classes  ?

  • C12N 1/21 - Bacteria; Culture media therefor modified by introduction of foreign genetic material
  • C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
  • C12N 15/34 - Proteins from DNA viruses
  • C12N 15/35 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
  • C12N 15/75 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
  • C12N 15/86 - Viral vectors

14.

INTEGRATIVE PLASMID

      
Application Number JP2021040411
Publication Number 2022/097647
Status In Force
Filing Date 2021-11-02
Publication Date 2022-05-12
Owner SYNPLOGEN CO., LTD. (Japan)
Inventor
  • Saito, Shunsuke
  • Tsuge, Kenji

Abstract

The present disclosure pertains to production of a virus vector plasmid. According to one aspect, the present disclosure provides a method for producing a virus vector plasmid having a sequence to be replicated in Bacillus subtilis. The method includes a step for forming a plasmid in a host cell by introducing, into the host cell, a nucleic acid that has a sequence to be replicated in Bacillus subtilis and that includes a nucleic acid sequence for producing a virus vector. In one embodiment, Bacillus subtilis could have the ability to form a plasmid from a nucleic acid acquired from outside, and therefore, in this method, the nucleic acid introduced dose not have be a plasmid.

IPC Classes  ?

  • C12N 15/86 - Viral vectors
  • C12N 1/21 - Bacteria; Culture media therefor modified by introduction of foreign genetic material
  • C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
  • C12N 15/34 - Proteins from DNA viruses
  • C12N 15/35 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
  • C12N 15/75 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus

15.

Method for preparing DNA unit composition, and method for creating concatenated DNA

      
Application Number 16876956
Grant Number 11408006
Status In Force
Filing Date 2020-05-18
First Publication Date 2021-01-14
Grant Date 2022-08-09
Owner SYNPLOGEN CO., LTD. (Japan)
Inventor
  • Tsuge, Kenji
  • Itaya, Mitsuhiro

Abstract

Provided are: a method for preparing a DNA unit composition in which the mol number of a plurality of DNA units is more uniform, and a method for creating concatenated DNA. The method for preparing a DNA unit composition has: a step for preparing solutions which contain a plurality of DNA units to which an added sequence is linked, and preparing a solution for each type of DNA unit and a step for, after preparing each of the solutions, measuring the concentration of the DNA unit in each of the solutions in a state where the added sequence is linked to the DNA unit, and on the basis of the results thereof, fractionating each of the solutions and making the mol number of the DNA unit in each of the solutions closer to being identical to one another.

IPC Classes  ?

  • C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
  • C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

16.

Synplogen

      
Application Number 1498799
Status Registered
Filing Date 2019-08-22
Registration Date 2019-08-22
Owner Synplogen Co., Ltd. (Japan)
NICE Classes  ? 42 - Scientific, technological and industrial services, research and design

Goods & Services

Research and development relating to DNA synthesis technology; technical advisory services and information technology services relating to DNA synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, quality control, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; technical advisory services and information technology services relating to genome synthesis technology; research and development, quality control, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells, all with genome synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems, all with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; technical advisory services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; information technology services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; testing, inspection or research relating to medical treatment or medical technology with genome synthesis technology; information technology services for testing, inspection or research relating to medical treatment or medical technology with genome synthesis technology; testing or research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; testing, inspection or research on agriculture, livestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; DNA synthesis services for others; research and development services in the field of gene expression systems; research and development services in the fields of microorganisms and cells; DNA sequence design services; research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; technical research; bacteriological research; biological research.

17.

OGAB

      
Application Number 1498800
Status Registered
Filing Date 2019-08-22
Registration Date 2019-08-22
Owner Synplogen Co., Ltd. (Japan)
NICE Classes  ? 42 - Scientific, technological and industrial services, research and design

Goods & Services

Research and development relating to DNA synthesis technology; technical advisory services and information technology services relating to DNA synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, quality control, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; technical advisory services and information technology services relating to genome synthesis technology; research and development, quality control, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells, all with genome synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems, all with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; technical advisory services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; information technology services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; testing, inspection or research relating to medical treatment or medical technology with genome synthesis technology; information technology services for testing, inspection or research relating to medical treatment or medical technology with genome synthesis technology; testing or research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; testing, inspection or research on agriculture, livestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; DNA synthesis services for others; research and development services in the field of gene expression systems; research and development services in the fields of microorganisms and cells; DNA sequence design services; research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; technical research; bacteriological research; biological research.

18.

Miscellaneous Design

      
Application Number 1497823
Status Registered
Filing Date 2019-08-22
Registration Date 2019-08-22
Owner Synplogen Co., Ltd. (Japan)
NICE Classes  ? 42 - Scientific, technological and industrial services, research and design

Goods & Services

Research and development relating to DNA synthesis technology; technical advisory services and information technology services relating to DNA synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, quality control, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; technical advisory services and information technology services relating to genome synthesis technology; research and development, quality control, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells, all with genome synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems, all with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; technical advisory services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; information technology services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; testing, inspection or research relating to medical treatment or medical technology with genome synthesis technology; information technology services for testing, inspection or research relating to medical treatment or medical technology with genome synthesis technology; testing or research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; testing, inspection or research on agriculture, livestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; DNA synthesis services for others; research and development services in the field of gene expression systems; research and development services in the fields of microorganisms and cells; DNA sequence design services; research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; technical research; bacteriological research; biological research.

19.

Miscellaneous Design

      
Serial Number 79271791
Status Registered
Filing Date 2019-08-22
Registration Date 2020-05-19
Owner Synplogen Co., Ltd. (Japan)
NICE Classes  ? 42 - Scientific, technological and industrial services, research and design

Goods & Services

Research and development relating to DNA synthesis technology; technical advisory services and * providing * information technology [ services ] relating to DNA synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, quality control, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; technical advisory services and * providing * information technology [ services ]relating to genome synthesis technology; research and development, quality control, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells, all with genome synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems, all with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; technical advisory services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; * providing * information technology [ services ] relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; testing, inspection or research relating to medical treatment or medical technology with genome synthesis technology; information technology services for testing, inspection or research relating to medical treatment or medical technology with genome synthesis technology; testing or research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; testing, inspection or research on agriculture, livestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; DNA synthesis services for others; research and development services in the field of gene expression systems; research and development services in the fields of microorganisms and cells; [ DNA sequence design services; ] research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; technical research in the field of microorganisms; bacteriological research; biological research

20.

SYNPLOGEN

      
Serial Number 79272215
Status Registered
Filing Date 2019-08-22
Registration Date 2020-08-04
Owner Synplogen Co., Ltd. (Japan)
NICE Classes  ? 42 - Scientific, technological and industrial services, research and design

Goods & Services

Research and development relating to DNA synthesis technology; technical advisory services and * providing * information technology consulting services relating to DNA synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, quality control for others, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; * providing * technical advisory services and information technology consulting services relating to genome synthesis technology; research and development, quality control for others, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells, all with genome synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems, all with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testing, inspection and research of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; * providing * technical advisory services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; information technology services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; testing, inspection and research relating to medical treatment or medical technology with genome synthesis technology; * providing * information technology consulting services for testing, inspection or research relating to medical treatment or medical technology with genome synthesis technology; testing and research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; testing, inspection or research on agriculture, livestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; DNA synthesis services for others for scientific research purposes; research and development services in the field of gene expression systems; research and development services in the fields of microorganisms and cells; [ DNA sequence design services for scientific research purposes; ] research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; technical research in the field of microorganisms; bacteriological research; biological research

21.

Method for preparing DNA unit composition, and method for creating concatenated DNA

      
Application Number 15113222
Grant Number 10655133
Status In Force
Filing Date 2014-09-05
First Publication Date 2017-01-12
Grant Date 2020-05-19
Owner SYNPLOGEN CO., LTD. (Japan)
Inventor
  • Tsuge, Kenji
  • Itaya, Mitsuhiro

Abstract

Provided are: a method for preparing a DNA unit composition in which the mol number of a plurality of DNA units is more uniform, and a method for creating concatenated DNA. The method for preparing a DNA unit composition has: a step for preparing solutions which contain a plurality of DNA units to which an added sequence is linked, and preparing a solution for each type of DNA unit; and a step for, after preparing each of the solutions, measuring the concentration of the DNA unit in each of the solutions in a state where the added sequence is linked to the DNA unit, and on the basis of the results thereof, fractionating each of the solutions and making the mol number of the DNA unit in each of the solutions closer to being identical to one another.

IPC Classes  ?

  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
  • C12N 15/03 - Bacteria
  • C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
  • C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA